drug_type
RELEVANT_DRUG
intervention_type
Antibody-drug conjugate
drug_description
Intravenous HER2-targeted antibody-drug conjugate: a humanized anti-HER2 IgG1 linked via a cleavable linker to a topoisomerase I inhibitor payload (DXd); binds HER2, is internalized, releases DXd to induce DNA damage, with Fc-mediated ADCC and bystander killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
trastuzumab deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER2 IgG1 linked via a cleavable linker to a topoisomerase I inhibitor payload (DXd). After binding HER2, the ADC is internalized and the linker is cleaved to release DXd, which induces DNA damage and cell death. The Fc domain can mediate ADCC, and the membrane-permeable payload enables bystander killing of adjacent tumor cells.
drug_name
Trastuzumab deruxtecan (T-DXd)
nct_id_drug_ref
NCT05633979